Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,090
  • Shares Outstanding, K 13,561
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,590 K
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.16
Trade ADIL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +117,629.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.14 +95.61%
on 09/24/20
4.00 -44.25%
on 09/29/20
+0.88 (+65.19%)
since 08/28/20
3-Month
1.14 +95.61%
on 09/24/20
4.00 -44.25%
on 09/29/20
+0.84 (+60.43%)
since 06/30/20
52-Week
1.00 +123.00%
on 03/18/20
4.00 -44.25%
on 09/29/20
+0.72 (+47.68%)
since 09/30/19

Most Recent Stories

More News
Adial Pharmaceuticals Announces Sale of 10,000 COVID-19 Antibody Rapid Test Devices

CHARLOTTESVILLE, VA / ACCESSWIRE / September 30, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for...

ADIL : 2.23 (-26.40%)
Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples

CHARLOTTESVILLE, VA / ACCESSWIRE / September 29, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions,...

ADIL : 2.23 (-26.40%)
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA

CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions,...

ADIL : 2.23 (-26.40%)
Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales

CHARLOTTESVILLE, VA / ACCESSWIRE / September 22, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions...

ADIL : 2.23 (-26.40%)
Adial Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

CHARLOTTESVILLE, VA / ACCESSWIRE / September 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions,...

ADIL : 2.23 (-26.40%)
Adial Pharmaceuticals to Present at The LD Micro 500 Virtual Conference on September 2nd

CHARLOTTESVILLE, VA / ACCESSWIRE / September 1, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions,...

ADIL : 2.23 (-26.40%)
ADILW : 0.3859 (-29.84%)
LD Micro - 360 Companies Set to Present this Week

LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACRX : 1.4200 (-0.70%)
ACER : 2.88 (-7.99%)
ACU : 23.03 (+0.78%)
AT.VN : 1.610 (-0.62%)
AEY : 1.9200 (+1.59%)
ADIL : 2.23 (-26.40%)
ADTX : 1.9500 (+4.84%)
ADXS : 0.4100 (-2.61%)
AEHR : 1.3900 (-0.71%)
AIM : 2.15 (+1.42%)
AIRI : 1.2200 (-3.17%)
ALIM : 4.86 (-6.18%)
ALJJ : 0.7251 (+0.29%)
ALLT : 9.10 (-1.62%)
ARCT : 42.90 (+0.40%)
AREC : 1.5000 (-1.32%)
AMS : 1.8100 (-7.65%)
ANVS : 4.81 (+0.84%)
APEN : 1.6900 (+1.20%)
APM : 2.68 (-43.70%)
AQMS : 0.9110 (-1.47%)
AQB : 4.48 (-1.54%)
ARTL : 0.9900 (+11.24%)
ARHH : 0.8980 (+4.77%)
ATOM : 10.45 (-0.95%)
ATOS : 2.42 (-3.97%)
AUTO : 3.14 (-1.57%)
AYRO : 2.96 (-6.62%)
AZRX : 0.7110 (-1.77%)
BELFA : 11.71 (+4.30%)
BCDA : 2.27 (-2.16%)
BIOC : 4.41 (-2.65%)
BHTG : 1.4500 (+18.85%)
BIOL : 0.2751 (+0.77%)
BKEP : 1.5400 (-3.14%)
ATDS : 0.0091 (-3.19%)
ASUR : 7.55 (+0.80%)
BEER.VN : 0.055 (+10.00%)
ANY : 2.47 (-4.63%)
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits

CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADIL : 2.23 (-26.40%)
LD Micro Announces Preliminary List of Presenters for the LD 500

LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACER : 2.88 (-7.99%)
ACU : 23.03 (+0.78%)
AEY : 1.9200 (+1.59%)
ADIL : 2.23 (-26.40%)
ADXS : 0.4100 (-2.61%)
AEHR : 1.3900 (-0.71%)
AIM : 2.15 (+1.42%)
AIRI : 1.2200 (-3.17%)
KERN : 3.64 (-2.15%)
ALIM : 4.86 (-6.18%)
ALLT : 9.10 (-1.62%)
AMS : 1.8100 (-7.65%)
ANVS : 4.81 (+0.84%)
APEN : 1.6900 (+1.20%)
APM : 2.68 (-43.70%)
AQB : 4.48 (-1.54%)
ARTL : 0.9900 (+11.24%)
ARHH : 0.8980 (+4.77%)
ATOM : 10.45 (-0.95%)
ATOS : 2.42 (-3.97%)
ACU.VN : 0.145 (+3.57%)
AUTO : 3.14 (-1.57%)
AYRO : 2.96 (-6.62%)
AYTU : 1.1900 (-0.83%)
AZRX : 0.7110 (-1.77%)
BLDP : 15.10 (unch)
BELFA : 11.71 (+4.30%)
BCDA : 2.27 (-2.16%)
BIOC : 4.41 (-2.65%)
BMRA : 6.93 (-3.35%)
BSGM : 4.93 (+1.02%)
BLNK : 10.31 (+3.20%)
BKEP : 1.5400 (-3.14%)
CLBS : 1.8000 (-4.26%)
CLXT : 5.49 (-4.69%)
ASUR : 7.55 (+0.80%)
BLGO : 0.1502 (-3.03%)
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland

Polish clinical sites initiated less than two weeks after regulatory approval

ADIL : 2.23 (-26.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

2nd Resistance Point 3.12
1st Resistance Point 2.68
Last Price 2.23
1st Support Level 1.95
2nd Support Level 1.66

See More

52-Week High 4.00
Fibonacci 61.8% 2.85
Fibonacci 50% 2.50
Last Price 2.23
Fibonacci 38.2% 2.15
52-Week Low 1.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar